Clinical Guides
Irritable Bowel Syndrome
A clinically focused, India-aware guide to making a positive diagnosis of irritable bowel syndrome, recognising when symptoms require investigation, and choosing proportionate diet, medicine and gut-brain care.
MedNext Academy | 12 min read
Irritable Bowel Syndrome
A clinically focused, India-aware guide to making a positive diagnosis of irritable bowel syndrome, recognising when symptoms require investigation, and choosing proportionate diet, medicine and gut-brain care.
Summary
Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction: recurrent abdominal pain occurs with altered stool frequency or form, without a structural lesion that explains the symptom pattern. It is real illness, not an imagined complaint, and can impair work, sleep, eating, sexual health and mood. Rome IV describes pain on average at least one day a week in the last three months, related to defecation and associated with a change in stool frequency or appearance; symptom onset should be at least six months earlier. Subtype from usual stool on symptomatic days: IBS with constipation (IBS-C), diarrhoea (IBS-D), mixed bowel habit (IBS-M), or unclassified IBS.
The practical distinction matters: IBS is usually a positive clinical diagnosis after a careful history, examination and a small, hypothesis-led test set. It is not a mandate to perform colonoscopy, CT, broad food-allergy panels or repeated stool testing in every patient. Conversely, a label must never silence new weight loss, anaemia, rectal bleeding, nocturnal diarrhoea, fever, an inflammatory examination, family cancer history or later-onset change in bowel habit. Those features change the pre-test probability and justify targeted exclusion of organic disease. [ACG, Table 1 and recommendations 1-4]
How Common Is It?
IBS is common in community and clinical practice, but a single prevalence figure is misleading because studies use different Rome versions, age groups, languages, sampling methods and definitions of healthcare seeking. The Indian INMA–Indian Society of Gastroenterology consensus reports population-based Indian estimates ranging from 0.4% to 4.2%, while noting a higher figure in one early urban Mumbai survey. These estimates should not be treated as an India-wide incidence rate: rural populations, adolescents, women who do not seek care, and people with post-infectious symptoms may be represented differently.
The condition is seen across sexes and ages, although consultation patterns can make one group appear over-represented. Many people self-manage, and diagnostic delay is common when abdominal pain is repeatedly investigated as infection or acidity rather than described alongside stool change. The individual burden is often greater than a prevalence number suggests: unpredictable urgency, constipation, bloating and pain can restrict travel, examinations, meals and work. A clinician should therefore measure severity and life impact, not merely count stools. [INMA–ISG, Statements 1-3 and Table 2]
Risk Factors
IBS has no single cause. A useful explanatory model links altered gut motility, visceral hypersensitivity, brain–gut signalling, microbiota and immune changes, learned symptom vigilance, sleep and psychological distress. A prior episode of infectious gastroenteritis can precede persistent symptoms, especially after severe or prolonged illness; this is association rather than proof that every ongoing symptom is infection. Family clustering may reflect genes, shared exposures and health behaviour. Coexisting dyspepsia, pelvic pain, migraine, fibromyalgia, anxiety or depression are common and should prompt compassionate whole-person assessment, not diagnostic dismissal.
Ask about antibiotics, metformin, magnesium products, laxatives, opioid use, NSAIDs, herbal preparations and artificial sweeteners; drugs may mimic or amplify bowel symptoms. Dietary restriction, eating disorder risk and food insecurity can both shape symptoms and make unplanned elimination diets dangerous. IBS does not itself cause colorectal cancer, coeliac disease or inflammatory bowel disease, but it may coexist with them. Recent travel, contaminated-water exposure, household diarrhoea, immunosuppression or tuberculosis risk changes the differential, especially in India. [ACG, sections on pathophysiology and diagnostic evaluation; INMA–ISG, Statements 6-12]
Diagnosis
History
Start with the patient’s own account of pain: site, timing, relation to defecation, frequency, severity, and what has changed. Record stool form using the Bristol scale, urgency, incontinence, straining, incomplete evacuation, mucus, bloating and symptom-free intervals. Establish Rome-compatible chronicity but do not make the patient recite criteria. Ask directly about bleeding, fever, nocturnal symptoms, unintentional weight loss, progressive course, vomiting, anaemia symptoms and family history of colorectal cancer, IBD or coeliac disease. Travel, unsafe water, recent acute diarrhoea, antibiotics, medications, menstrual and pregnancy history, diet restriction, mood, sleep and functioning materially alter assessment.
Examination
Measure weight and vital signs; look for pallor, dehydration, fever, lymphadenopathy and oral ulcers. Perform a focused abdominal examination for mass, distension, tenderness, organomegaly or peritonism. Rectal examination is selective but important with bleeding, suspected impaction, pelvic-floor disorder or alarm symptoms. A normal examination supports, but cannot prove, a functional diagnosis.
Investigations
In a typical presentation without alarms, use limited testing. Full blood count and inflammatory markers are reasonable when anaemia or inflammation is plausible; coeliac serology is recommended in diarrhoea-predominant or mixed IBS while the patient is eating gluten. Faecal calprotectin or lactoferrin and CRP help distinguish IBD from IBS-D when suspicion exists. Stool microbiology, parasite testing, colonoscopy, imaging and breath tests are reserved for exposure, warning signs, age-appropriate screening or another specific question. A negative test should end that branch of work-up; serial low-yield testing reinforces uncertainty. [ACG, Table 2 and recommendations 1-8; current guidelines, recommendations 1.1.1-1.1.2]
Differential Diagnosis
The key is not to exclude every conceivable disease; it is to avoid missing diseases that plausibly explain the presentation. Chronic diarrhoea with anaemia, weight loss, nocturnal stooling, raised calprotectin or blood requires consideration of IBD, colorectal neoplasia, microscopic colitis, coeliac disease, bile-acid diarrhoea, pancreatic insufficiency, endocrine disease and chronic infection. In India, amoebiasis, giardiasis and other parasites should be tested for when exposure, outbreak, travel or persistent watery diarrhoea makes them likely, rather than as an automatic screen for all IBS. Tuberculosis enters the differential when constitutional symptoms, mass, ascites, imaging or pulmonary findings point to it; typical IBS alone does not establish that concern.
Constipation may reflect medicines, hypothyroidism, hypercalcaemia, neurological disease, pelvic-floor dyssynergia or a colorectal obstruction. Pain centred in the pelvis may reflect endometriosis, ovarian pathology, bladder pain syndrome or chronic pelvic pain; symptoms that track menstruation deserve gynaecological assessment. Lactose or fructan intolerance can amplify symptoms, but commercial IgG food tests do not diagnose intolerance. SIBO testing is not a default explanation for bloating because test performance and clinical meaning are limited. [ACG, diagnostic testing recommendations and discussion of alarm features; INMA–ISG, Statements 13-17]
Management
A credible explanation is treatment. Explain that the bowel is sensitive and dysregulated rather than damaged, agree realistic targets—less pain, predictable stooling, restored activity—and schedule review rather than offering endless tests. Regular meals, adequate fluids, gradual activity, sleep support and attention to stress are reasonable first steps, but should not be presented as a cure or as blame. Use a symptom and stool diary briefly to identify patterns, not to create food fear.
Diet should be sequenced. Start with accessible, culturally appropriate basic advice and review fibre quality: soluble fibre such as psyllium can help global symptoms, whereas abrupt bran or insoluble-fibre escalation can worsen pain and gas. A dietitian-guided low-FODMAP trial may help selected people, but it has three stages—short restriction, reintroduction, then personalisation—and should not become permanent broad avoidance. Evidence is not equally strong for every food rule, probiotic strain, Ayurveda preparation or microbiome test; avoid claiming universal benefit.
Choose treatment by the dominant symptom and reassess response. Gut-directed CBT, hypnotherapy or other psychological therapy can help refractory IBS and does not imply symptoms are voluntary. Shared decisions should include cost, availability, pregnancy, coexisting anxiety/depression and the person’s own treatment goals. [ACG, recommendations 9-27; current guidelines, sections 1.2.1 and 1.2.3]
Prescribing Information
Prescribing is symptom-directed, not one-size-fits-all. For IBS-D, loperamide can reduce stool frequency and urgency but does not reliably relieve global pain; titrate cautiously and avoid it in bloody diarrhoea, fever, suspected invasive infection, marked distension or constipation. Antispasmodics may be tried for cramping, although individual preparations and evidence vary. For IBS-C, osmotic laxatives may improve stool frequency but often do less for pain; avoid lactulose when it worsens bloating. Secretagogues and selected prescription agents have more specific evidence in some countries, but Indian availability, labelling and affordability differ.
Low-dose tricyclic antidepressants may reduce global IBS symptoms and pain, especially with diarrhoea, but counsel about sedation, dry mouth, constipation, orthostatic symptoms, cardiac risk and overdose safety. SSRIs are not interchangeable with TCAs; consider them chiefly when a mood disorder or other indication guides the decision. Assess suicide risk before any antidepressant. Avoid chronic opioids: they can worsen constipation, dependence and abdominal pain. Antibiotics, including rifaximin where licensed, are not a casual response to bloating and require a defined indication. Check renal, hepatic, pregnancy, lactation, interaction and local-label constraints before prescribing. [ACG, recommendations 14-25; current guidelines, recommendations 1.2.2.1-1.2.2.8]
When to Refer
Refer urgently to gastroenterology or an appropriate cancer/inflammatory bowel pathway for rectal bleeding without a clear benign source, iron-deficiency anaemia, unintentional weight loss, nocturnal diarrhoea, persistent raised inflammatory markers, a palpable mass, progressive symptoms, strong family history, or symptoms beginning later in life with a change in bowel habit. The referral question should be specific: suspected IBD, coeliac disease, microscopic colitis, malignancy, chronic infection, bile-acid diarrhoea or pelvic-floor disorder. Include chronology, Bristol stool pattern, alarms, weight trajectory, relevant exposure, medication list and completed results to prevent repetition.
Routine gastroenterology referral is reasonable when diagnostic uncertainty remains after proportionate assessment, symptoms substantially impair life despite primary-care management, medicines are difficult to balance, or a restricted diet needs expert support. Refer to a dietitian for low-FODMAP work, undernutrition, diabetes, renal disease, pregnancy or an eating-disorder concern. Pelvic-floor physiotherapy or specialist physiology assessment may help refractory constipation with evacuation difficulty. Psychological referral should be framed as a gut-brain treatment option alongside medical care, not as proof that symptoms are psychological. [current guidelines, recommendations 1.1.1-1.1.2 and 1.2.3; INMA–ISG, Statements 13-28]
Red Flags
Seek same-day assessment for severe or escalating abdominal pain with guarding, a rigid abdomen, persistent vomiting, marked distension, inability to pass stool or flatus, syncope, fever with toxicity, confusion, severe dehydration, melaena or substantial rectal bleeding. These may indicate obstruction, perforation, sepsis, major haemorrhage or another acute illness rather than IBS. A patient with diarrhoea and fever, blood, recent antibiotics or immunosuppression needs infection and colitis assessment before antidiarrhoeal treatment.
Prompt review—not simply reassurance—is needed for weight loss, anorexia, persistent nocturnal symptoms, new symptom onset after around 50 years, family history of colorectal cancer/IBD/coeliac disease, palpable mass, anaemia, raised CRP or faecal inflammatory marker, or a sustained departure from an established IBS pattern. New symptoms during follow-up matter as much as features at diagnosis. Pregnancy with severe vomiting, dehydration or bleeding, and any child or adolescent with faltering growth, require age-appropriate pathways rather than adult IBS assumptions. In a patient already labelled with IBS, a new change must be assessed on its own merits; the old label does not lower the urgency of bleeding, fever, abdominal distension or progressive decline. The presence of one feature does not name the diagnosis; it changes the safety threshold for examination, tests and referral. [current guidelines, section 1.1 and follow-up recommendation 1.2.5.1; ACG, alarm-feature discussion]
Indian Clinical Context
Indian practice must keep both under-investigation and indiscriminate testing in view. The Indian consensus supports symptom-based diagnosis but recognises different infection exposures, medicine availability and healthcare access. A history of unsafe water, travel, outbreak contact, persistent post-infectious diarrhoea, immunosuppression or systemic symptoms should lead to focused stool or infection evaluation. It should not turn every patient with longstanding pain and variable stool into an open-ended parasite work-up. Coeliac testing, calprotectin, endoscopy and dietetic advice may be variably available; document the clinical question and arrange referral when an unavailable test is likely to change management.
Low-FODMAP advice needs translation into local foods and household budgets. It is not synonymous with avoiding rice, wheat, pulses, milk, onion, garlic and fruit forever. A qualified dietitian should preserve adequate protein, fibre, calcium and energy, particularly in vegetarian diets, pregnancy, older age and food insecurity. Brand-specific probiotics, herbal remedies and over-the-counter antispasmodics vary in contents and evidence; ask explicitly about them and report suspected adverse effects through appropriate Indian pharmacovigilance channels. For patients travelling long distances, put the positive diagnosis, test rationale, medicine plan and explicit return triggers in the record so a different clinician can continue safe care. This guide does not replace current Indian labels or a clinician who can examine the patient. [INMA–ISG, Statements 13-28 and discussion of Indian drug availability]
NMC Competency Mapping
This topic maps to NMC undergraduate outcomes across medicine, pharmacology, pathology, microbiology, nutrition, psychiatry and AETCOM. At Know level, learners should define IBS as a disorder of gut-brain interaction, state Rome-compatible symptom features, classify stool subtypes and list alarm features. At Know How level, they should distinguish a positive clinical diagnosis from a diagnosis made only after exhaustive exclusion; select full blood count, coeliac serology, inflammatory markers, faecal calprotectin, stool tests, endoscopy or imaging only when the history supplies a purpose; and recognise common mimics.
At Show How level, a learner should take a non-stigmatising bowel history, use the Bristol stool scale, ask about food insecurity and mood, explain uncertainty without false reassurance, and safety-net new alarms. They should counsel on a time-limited diet trial, safe laxative or loperamide use, and when to stop self-treatment. Prescribing antidepressants, interpreting abnormal inflammatory markers, and invasive tests require supervision and local policy. AETCOM emphasis is on validating symptoms, avoiding gendered or psychiatric dismissal, respecting privacy around bowel habits, and shared decisions where access and affordability limit options. [NMC CBME Curriculum 2024, medicine, pharmacology, psychiatry, nutrition and AETCOM domains]
Key Exam Pearls for NEET PG
IBS requires recurrent abdominal pain plus relation to defecation and change in stool frequency or form; bloating alone is not sufficient. Rome IV uses pain on average at least one day per week in the last three months, with onset at least six months before diagnosis. Classify IBS-C, IBS-D and IBS-M by abnormal stool form on days with abnormal bowel movements. A positive diagnosis follows a focused history, examination and limited tests; it is not synonymous with a normal colonoscopy.
In a patient with diarrhoea-predominant symptoms, remember coeliac serology and consider CRP plus faecal calprotectin/lactoferrin when IBD is plausible. Blood in stool, weight loss, anaemia, fever, nocturnal diarrhoea, mass and family history are warning signals, not diagnostic labels. Soluble fibre is preferred over insoluble bran for global symptoms. Low-FODMAP therapy is a structured, time-limited elimination and reintroduction process, not lifelong restriction.
Loperamide improves diarrhoea/urgency more reliably than pain. TCAs can improve global symptoms but commonly constipate and sedate; avoid simplistic claims that SSRIs are equivalent. Chronic opioids are unsafe for functional abdominal pain. Psychological therapies address gut-brain signalling and can be evidence-based care. In Indian examinations, balance functional diagnosis with infectious, coeliac and inflammatory mimics when history indicates them. [ACG, Table 1, Table 2 and diet/pharmacotherapy recommendations]
Frequently Asked Questions
Is irritable bowel syndrome a diagnosis of exclusion or a positive diagnosis?
For a typical chronic pattern without alarm features, IBS is a positive symptom-based diagnosis supported by a focused history, examination and limited tests chosen to exclude plausible alternatives. It is not necessary—or safe—to keep repeating broad investigations until every rare disease is excluded. The opposite error is to label symptoms IBS without asking about bleeding, weight loss, anaemia, nocturnal diarrhoea, fever, medication and exposure history. New warning signs later reopen the diagnostic question.
Should every person with IBS follow a low-FODMAP diet permanently?
No. A low-FODMAP approach is a short, structured trial for selected patients, ideally with a dietitian: restriction for a few weeks, systematic reintroduction, then a personalised least-restrictive diet. Long-term blanket avoidance can reduce fibre variety, nutritional adequacy and enjoyment of food, and may be expensive. Basic regular-meal advice and soluble-fibre adjustment are often a more accessible first step. A response to restriction does not prove a food allergy or justify eliminating many foods indefinitely.
Which medicines help IBS pain, diarrhoea and constipation safely?
Treatment follows the dominant symptom and the person’s risks. Loperamide may reduce diarrhoea and urgency but does not reliably treat pain. Osmotic laxatives may improve stool frequency in constipation but may not relieve pain. Antispasmodics and low-dose tricyclic antidepressants can be considered for pain, with attention to anticholinergic and cardiac effects. Prescription drugs differ by subtype, country, label and availability. Avoid chronic opioids and do not self-treat blood, fever or severe pain as IBS.
Can stress cause IBS symptoms even when tests are normal?
Stress can amplify gut-brain signalling, pain sensitivity, sleep disruption and bowel habit, but it is neither an imagined cause nor a replacement for clinical assessment. IBS has biological, behavioural and social contributors. Explaining this connection can make CBT, gut-directed hypnotherapy, sleep treatment or mental-health care available as additional evidence-based tools. A normal test result is reassuring only in the context of a careful assessment; it should never be used to tell a patient that symptoms are trivial.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic